Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Cipla
Accenture
Teva
QuintilesIMS
Dow
McKesson
Queensland Health
Deloitte
Chubb

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,148,207 protect, and when does it expire?


Patent ► Subscribe protects OFORTA and is included in one NDA.

This patent has thirty-six patent family members in thirty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: ► Subscribe

Title:Oral fludara of high-purity formulation with quick release of active ingredient
Abstract:This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
Inventor(s): Heil; Wolfgang (Stelle, DE), Tistam; Ulf (Wezembeek Oppem, BE), Lipp; Ralph (Berlin, DE), Tack; Johannes-Wilhelm (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:10/324,141
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
OFORTA
fludarabine phosphate
TABLET;ORAL022273-001Dec 18, 2008DISCNNoNo► Subscribe► SubscribeY TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 64 510Dec 20, 2001

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina037965► Subscribe
Austria303797► Subscribe
Australia2002349043► Subscribe
Brazil0215265► Subscribe
Canada2471396► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
US Army
Federal Trade Commission
Queensland Health
Citi
Cerilliant
Express Scripts
Healthtrust
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot